Education
About Us
Working with TipRanks
Follow Us
Roivant Sciences (ROIV)
NASDAQ:ROIV
Earnings Data
Report Date
Aug 18, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.25Last Year’s EPS
0.12Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 29, 2025
|% Change Since: 7.82%
|Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment|Neutral
Roivant's earnings call presented a strong financial position and promising developments in its pipeline, particularly with Brepocitinib and IMVT-1402. However, challenges remain in terms of competition in the FcRn space and ongoing litigation. The sentiment is balanced with significant growth potential but also notable risks.Company Guidance
In the recent earnings call for Roivant's fourth quarter of fiscal year 2024, the company provided guidance on several key metrics and strategic initiatives. CEO Matt Gline highlighted that fiscal year 2025 is crucial for Roivant, with significant progress in their clinical pipeline and litigation efforts. The company is particularly excited about the potential registrational data for Brepocitinib in dermatomyositis, which they expect to readout in the second half of the year. This data could position Brepocitinib as the first novel oral DM therapy on the market. In terms of financials, Roivant reported nearly $5 billion in cash on the balance sheet as of March 31, 2025, and has repurchased $1.3 billion of its own stock, reducing its share count by almost 15%. Additionally, the company is actively engaging in LNP litigation with Moderna and Pfizer/BioNTech, expecting to move to trial soon. Roivant is also advancing its late-stage pipeline, including IMVT-1402 and mosliciguat, with multiple potentially registrational studies underway.Strong Cash Position and Capital Allocation
Roivant has just under $5 billion in cash with no debt, supporting the current pipeline to profitability. $2 billion is reserved for pipeline expansion, and the company has repurchased $1.3 billion of its own stock, reducing the share count by nearly 15%.
Promising Pipeline Developments
The company is excited about the upcoming registrational data from the Brepocitinib study in dermatomyositis, a potential first novel oral DM drug. IMVT-1402 is seen as a potential best-in-class anti-FcRn with multiple indications in play.
Advancements in FcRn Franchise
Roivant's IMVT-1402 is claimed to have a favorable safety profile and robust IgG lowering, with ongoing clinical progress across multiple indications including Graves' disease and Sjogren's.
Ongoing Litigation
Roivant is in the narrowing and summary judgment phase of its LNP litigation with Moderna and Pfizer/BioNTech, expected to move to trial soon.
ROIV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ROIV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 29, 2025 | $10.62 | $11.30 | +6.40% |
Feb 10, 2025 | $10.89 | $10.79 | -0.92% |
Nov 12, 2024 | $11.81 | $11.64 | -1.44% |
Aug 08, 2024 | $10.17 | $10.85 | +6.69% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Roivant Sciences (ROIV) report earnings?
Roivant Sciences (ROIV) is schdueled to report earning on Aug 18, 2025, TBA Not Confirmed.
What is Roivant Sciences (ROIV) earnings time?
Roivant Sciences (ROIV) earnings time is at Aug 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ROIV EPS forecast?
ROIV EPS forecast for the fiscal quarter 2025 (Q1) is -0.25.